본문으로 건너뛰기
← 뒤로

CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.

1/5 보강
Journal of clinical and experimental hematopathology : JCEH 2026 Vol.66(1) p. 45-51
Retraction 확인
출처

Moriwaki K, Tatetsu H, Higuchi Y, Nakamura T, Naito A, Yamada A, Shichijo T, Tokunaga K, Gushima R, Shiota T, Mikami Y, Nosaka K, Tanaka Y, Karube K, Yasunaga JI

📝 환자 설명용 한 줄

Primary gastrointestinal lymphoma accounts for only 1-4% of all gastrointestinal malignancies, yet the gastrointestinal tract is the most common extranodal site of non-Hodgkin lymphoma, comprising 10-

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Moriwaki K, Tatetsu H, et al. (2026). CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.. Journal of clinical and experimental hematopathology : JCEH, 66(1), 45-51. https://doi.org/10.3960/jslrt.25057
MLA Moriwaki K, et al.. "CD5-positive diffuse large B-Cell lymphoma presenting with protein-losing enteropathy.." Journal of clinical and experimental hematopathology : JCEH, vol. 66, no. 1, 2026, pp. 45-51.
PMID 41922227
DOI 10.3960/jslrt.25057

Abstract

Primary gastrointestinal lymphoma accounts for only 1-4% of all gastrointestinal malignancies, yet the gastrointestinal tract is the most common extranodal site of non-Hodgkin lymphoma, comprising 10-15% of all non-Hodgkin lymphomas. Among these, diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue lymphoma frequently affect the stomach and small intestine. Protein-losing enteropathy associated with malignant lymphoma is exceedingly rare, particularly when caused by CD5-positive DLBCL. We report the case of a 60-year-old woman with a four-year history of refractory diarrhea and progressive lower extremity edema, ultimately diagnosed with CD5-positive DLBCL of the small intestine. Diagnostic workup revealed hypoproteinemia with significant protein leakage in the ascending colon and distal small intestine. Double-balloon endoscopy demonstrated shallow, wide ulcers with patchy whitish exudates, and histopathology confirmed a diagnosis of de novo CD5-positive DLBCL. Chemotherapy with rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH-R) led to prompt improvement in serum albumin levels and resolution of the protein-losing enteropathy. Subsequent high-dose chemotherapy with autologous stem cell transplantation has maintained remission. Given the rarity of this presentation and its strong similarity to a previously reported case of CD5-positive DLBCL with protein-losing enteropathy, we propose that this might represent a distinct clinical entity.

MeSH Terms

Humans; Female; Lymphoma, Large B-Cell, Diffuse; Protein-Losing Enteropathies; Middle Aged; CD5 Antigens; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Vincristine; Doxorubicin; Rituximab